Akkus Mehmet N, Ormam Adil, Seyis Sabri, Baran Çagdas, Görür Aysegül, Bilen Mehmet N
.
Clin Invest Med. 2016 Jun 16;39(3):E79-87. doi: 10.25011/cim.v39i3.26796.
The purpose of this study was to determine whether the plasma levels of soluble extracellular matrix metalloproteinase inducer (EMMPRIN) differed among the patients with ST-elevation myocardial infarction (STEMI), non-STEMI (NSTEMI) and stable coronary artery disease (CAD) and the healthy controls, and to identify the factors associated with the differences in plasma levels of this this protein among patients in these groups.
Plasma EMMPRIN levels were compared among four age- and sex-matched groups of patients with STEMI, NSTEMI and stable CAD and healthy controls (n=44 per group), then logistic regression and correlation analyses were conducted for the whole acute myocardial infarction (AMI) patients group.
EMMPRIN levels were significantly higher in the STEMI (39.4±9.2ng/mL) and NSTEMI (37.1±10.5ng/mL) groups than in either the stable CAD (27.5±4.7ng/mL) or control (24.5±5.8ng/mL) groups (p.
本研究旨在确定可溶性细胞外基质金属蛋白酶诱导剂（EMMPRIN）的血浆水平在ST段抬高型心肌梗死（STEMI）、非ST段抬高型心肌梗死（NSTEMI）、稳定型冠状动脉疾病（CAD）患者及健康对照者之间是否存在差异，并确定与这些组患者中该蛋白血浆水平差异相关的因素。
比较年龄和性别匹配的STEMI、NSTEMI、稳定型CAD患者及健康对照者四组（每组n = 44）的血浆EMMPRIN水平，然后对整个急性心肌梗死（AMI）患者组进行逻辑回归和相关性分析。
STEMI组（39.4±9.2ng/mL）和NSTEMI组（37.1±10.5ng/mL）的EMMPRIN水平显著高于稳定型CAD组（27.5±4.7ng/mL）或对照组（24.5±5.8ng/mL）（p......（原文此处不完整）
